Based on the comprehensive data analysis, CSL appears to be currently overvalued for the following key reasons:
The stock's PE ratio has significantly increased from 14.46 in 2022 to 21.96 in 2023, indicating substantial valuation expansion despite declining fundamentals.
Revenue declined by 15.8% from $5.45B in 2022 to $4.59B in 2023, while net income dropped by 16.9% to $765.6M, showing deteriorating business performance.
Technical indicators suggest bearish momentum with RSI at 38.64 and negative MACD, while the stock trades below key moving averages including the 200-day SMA of $414.70.
Recent analyst price targets averaging $493.20 appear optimistic given the fundamental deterioration and technical weakness, suggesting downside risk from current levels.
The stock's current price of $357.81 represents poor value given the declining growth metrics and profitability, despite a recent DCF analysis suggesting potential undervaluation.